Literature DB >> 18312769

Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy.

Ahmad Elesber1, Rick A Nishimura, Charanjit S Rihal, Steve R Ommen, Hartzell V Schaff, David R Holmes.   

Abstract

It is important to identify patients with hypertrophic cardiomyopathy (HC) who have labile left ventricular outflow tract (LVOT) obstruction for consideration of ventricular septal reduction therapy. Although Doppler echocardiography has become the diagnostic modality to assess LVOT obstruction, it may not identify all patients with labile obstruction. This study assessed the diagnostic value of cardiac catheterization using isoproterenol challenge in 25 patients with HC in whom an LVOT obstruction (gradient >or=50 mm Hg) was clinically suspected, but not diagnosed using Doppler echocardiography. These patients underwent cardiac catheterization using a transseptal approach with isoproterenol challenge. During isoproterenol infusion, the gradient increased to >or=50 mm Hg in 14 patients and remained <50 mm Hg in 11 patients. Ten patients subsequently underwent surgical myectomy, 6 patients underwent alcohol septal ablation, and 9 patients were managed medically. Median follow-up was 26 months. Of patients who had a provoked gradient >50 mm Hg during isoproterenol infusion, 8 patients who underwent septal myectomy and 5 of 6 patients who underwent alcohol septal ablation had sustained alleviation of symptoms at follow-up. In conclusion, cardiac catheterization with isoproterenol challenge may identify patients with HC who may benefit from septal reduction therapy for whom the initial noninvasive evaluation does not show severe obstruction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18312769     DOI: 10.1016/j.amjcard.2007.09.111

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Synthesis, isolation, identification and characterization of new process-related impurity in isoproterenol hydrochloride by HPLC, LC/ESI-MS and NMR.

Authors:  Neeraj Kumar; Subba Rao Devineni; Prasad Reddy Gajjala; Shailendra Kumar Dubey; Pramod Kumar
Journal:  J Pharm Anal       Date:  2017-05-10

2.  Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy.

Authors:  James W Malcolmson; Rebecca K Hughes; Abhishek Joshi; Jackie Cooper; Alexander Breitenstein; Matthew Ginks; Steffen E Petersen; Saidi A Mohiddin; Mehul B Dhinoja
Journal:  Ther Adv Cardiovasc Dis       Date:  2022 Jan-Dec

3.  Provocation of left ventricular outflow tract obstruction using nitrate inhalation in hypertrophic cardiomyopathy: Relation to electromechanical delay.

Authors:  Hala Mahfouz Badran; Waleed Abdou Ibrahim; Naglaa Faheem; Rehab Yassin; Tamer Alashkar; Magdi Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2015-04-24

Review 4.  Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.

Authors:  Mark V Sherrid
Journal:  Curr Cardiol Rev       Date:  2016
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.